Enteric Nervous System: Myenteric & Meissner's Plexus

Meissner's plexus (submucosal plexus) regulates all functions of the mucosa. It controls glandular secretion (stimulating or inhibiting mucous glands), regulates blood flow to the mucosa, and influences the muscularis mucosae to produce movements related to nutrient assimilation. The plexus receives input from both sympathetic and parasympathetic nervous systems.

The submucosal plexus integrates sensory signals and regulates: (1) Secretion of digestive enzymes and fluids; (2) Blood flow to the digestive tract; (3) Local absorption of nutrients; (4) Mucosal blood flow. This plexus acts as a local control center that coordinates the secretory and absorptive functions of the digestive tract based on the presence of food and other stimuli.

The submucosal plexus of Meissner is located in the submucosa of the gastrointestinal tract. Its primary function is to control intestinal secretion. The neurons in this plexus connect to glands present in the gastrointestinal epithelium, thereby controlling intestinal secretion, absorption, and local blood flow. Since the submucosa contains the most important blood vessels that nourish all layers of the intestine, this plexus plays a crucial role in regulating local blood supply.

The submucosal plexus (Meissner's plexus) contains sensory neurons (including stretch and chemoreceptors), motor neurons that regulate glandular secretion, and neurons controlling blood vessel smooth muscle. It extends from the esophagus to the rectum and manages local gut functions including secretion of mucus and digestive enzymes, as well as blood flow regulation to the gastrointestinal tract.

The submucosal plexus (Meissner's plexus) is located in the submucosal layer and is primarily responsible for the secretion of glandular components including hormones, enzymes, and other secretions. It also regulates intestinal absorption and controls local blood flow via the muscularis mucosa.

Diagnosis begins with barium enema showing proximal colon dilation meeting a narrowed distal rectum, but definitive confirmation requires rectal biopsy demonstrating absence of ganglion cells. Treatment involves surgical pull-through procedure where the aganglionic colon segment is removed and the healthy bowel is pulled through to the rectum. Clinical vignettes demonstrate classic presentations including failure to pass meconium, persistent abdominal distension, vomiting, and temporary relief from digital rectal exam without sustained stool passage.

Diagnosis requires clinical suspicion combined with histopathological confirmation via rectal biopsy demonstrating complete absence of ganglion cells. Barium enema may show characteristic transition zones. Manometry demonstrates absence of rectal inhibitory reflex. Treatment involves resection of the aganglionic segment with primary anastomosis placed as low as possible (typically 7 cm above pectinate line). Modern techniques allow primary pull-through procedures without initial colostomy, performed laparoscopically or openly. Postoperative care focuses on preventing infection and ensuring proper anastomotic healing. The goal is to restore normal bowel function while minimizing complications.

Diagnosis involves: (1) Clinical suspicion based on ribbon-like stool and chronic constipation, (2) Abdominal X-ray showing dilated bowel loops and air-fluid levels, (3) Barium enema to identify the transition zone between affected and normal bowel, and (4) Rectal biopsy - the gold standard test showing absence of ganglion cells and hypertrophied nerve trunks. Rectal manometry demonstrates absence of the recto-anal inhibitory reflex. Intestinal obstruction shows presence of ganglion cells, distinguishing it from Hirschsprung disease. The primary treatment is surgical. The pull-through procedure involves removing the aganglionic segment and anastomosing the normal bowel to the anus. Types include: (1) Swenson procedure - direct removal and connection, (2) Duhamel procedure - creates a pouch from normal bowel, (3) Soave procedure - mucosal stripping and anastomosis. In severe cases or neonates with enterocolitis, initial management involves colostomy (right or left). After stabilization, definitive surgery is performed.

This segment covers the histopathological diagnosis and surgical management of Hirschsprung disease. Histopathological findings include absence of ganglion cells, hypertrophic nerve fibers (cutoff 40 micrometers), and increased acetylcholinesterase activity. Calretinin staining identifies ganglion cells (absent in Hirschsprung disease). Preoperative workup includes reviewing all records and biopsies, confirming the biopsy was taken from the correct site (stoma opening), and ensuring the biopsy shows hypoganglionosis. If a stoma biopsy shows hypoganglionosis but the child is passing stools normally, this may indicate the biopsy was taken from a transition zone. During definitive surgery, the last 3 cm of the pull-through should be discarded to ensure only ganglionated bowel is brought down. The three main pull-through procedures are Duhamel, Swenson, and Soave. Duhamel is commonly performed, easy to learn, and considered to have the best postoperative outcome. Swenson is the most anatomical procedure but is technically demanding. The choice of procedure should be based on surgeon comfort, hospital facilities, and patient factors.

Hirschsprung's disease is characterized by absence of ganglion cells in rectal biopsy. The affected segment is contracted while proximal segment is dilated. Management: confirm diagnosis with rectal biopsy, temporary colostomy, then definitive procedures (Swenson, Duhamel, or Soave procedures).

The gut-brain axis describes the bidirectional communication network between the brain and the enteric nervous system in the gut, involving approximately 100 million neurons and the vagus nerve as the primary connection; this axis is regulated by the gut microbiome containing trillions of microorganisms that influence mood, behavior, immune function, and susceptibility to diseases such as inflammatory bowel disease, type 2 diabetes, and anxiety/depression, with evidence showing that fecal microbiota transplants can transfer these effects between individuals.

The gut-brain axis represents a complex bidirectional communication system between the cranial brain and enteric nervous system (the 'second brain' with 100 million neurons). The enteric nervous system controls basic gastrointestinal functions and produces 80% of serotonin and 50% of dopamine. Communication occurs through three pathways: vagal (direct neural), circulatory (metabolites like short-chain fatty acids), and immune (cytokines). The microbiota serves as a communication hub connecting nervous, endocrine, and immune systems. Each system has receptors for mediators of other systems, and cells can produce mediators of other systems. The microbiota produces neurotransmitters and hormones, with specific bacterial species producing specific neurotransmitters like serotonin, GABA, and dopamine. The microbiota affects the HPA axis, regulating cortisol release and stress response. It presents molecular patterns to the immune system, activating immune cells that produce cytokines affecting brain neurons and glial cells. The microbiota can facilitate cytokine release that stimulates neurogenesis. Clinical studies with prebiotics and probiotics have been conducted in neurological diseases including encephalopathy, multiple sclerosis, constipation in cerebral palsy, and epilepsy. This demonstrates that neurodegenerative pathologies and neurological alterations relate to intestinal microbiota state, whether as cause or consequence.

The gut-brain axis represents the bidirectional communication between the intestinal microbiota and the central nervous system. The enteric nervous system contains approximately 500 million neurons and operates with significant independence, controlling intestinal functions. The dense innervation of the intestines is partly dependent on the intestinal microbiota itself. Intestinal bacteria produce an infinite variety of molecules including neurotransmitters, vitamins, secondary bile acids, amino acids, and short-chain fatty acids. These molecules reach the brain through the bloodstream or nervous system, particularly via the vagus nerve. Short-chain fatty acids, produced from fiber fermentation, are involved in neuroplasticity, gene expression, and immune modulation. The typical Western diet is poor in fiber, weakening the intestinal wall and facilitating pathogen entry. Several neurotransmitters are produced by the intestinal microbiota, including GABA and serotonin. The intestine is the main producer of serotonin in the body, acting primarily locally.

The gut and brain communicate bidirectionally. The vagus nerve, the longest of the 12 cranial nerves, is the main communication channel between hundreds of millions of neurons in the enteric nervous system and the central nervous system. The enteric nervous system of the digestive tract is so rich in neurons that many scientists call it the 'second brain.' It controls muscles, immune cells, and hormones, and produces substances like serotonin. Approximately 80-90% of the body's serotonin is produced by neurons in the gut, more than the brain in the head. Neurologists and psychiatrists are recognizing that the gut brain may not be secondary at all—it may function independently from the main brain and control many functions without commands or assistance from the brain.

The gut contains a nervous system (enteric nervous system) with nearly as many neurons as the spinal cord, capable of learning and even influencing dreams. The gut produces melatonin, which synchronizes different intestinal sections rather than primarily regulating sleep. This gut-brain axis involves bidirectional communication between the digestive system and the brain, with the gut producing hormones and neurotransmitters that affect mood, cognition, and overall health.

Gastrointestinal motility disorders disrupt the coordinated neuromuscular functioning of the GI tract, leading to various conditions: slow transit constipation results from poor stool movement through the colon, pelvic floor dysfunction involves dis-coordinated muscles preventing stool expulsion, diarrhea-associated motility disorders involve hyperactive colon muscles, GERD occurs when the esophageal sphincter is too relaxed allowing stomach acid reflux, gastroparesis delays stomach emptying due to muscle discoordination, and achalasia involves hyperactive sphincter muscles making food passage difficult.

Functional gastrointestinal disorders include dyspepsia (indigestion), gastroesophageal reflux disease (GERD), gastroparesis (delayed stomach emptying), irritable bowel syndrome (IBS), chronic constipation, pelvic floor disorders, and achalasia (esophageal motility disorder). These conditions involve dysfunction of the GI tract without identifiable structural abnormalities.

Gastroparesis is associated with other motility disorders: (1) Constipation - present in 40% of patients; (2) Intestinal transit disorders - present in up to 64% of patients; (3) Achalasia - rare association. These associations suggest that patients with gastroparesis may have broader gastrointestinal motility dysfunction.

Esophageal motility disorders include achalasia cardia (failure of LES to relax and absence of peristalsis), diffuse esophageal spasm (simultaneous non-peristaltic contractions), and scleroderma esophageal involvement (loss of smooth muscle peristalsis). Only the lower esophageal sphincter can develop achalasia because it is under autonomic nervous system control (parasympathetic stimulation via vagus nerve), while the upper esophageal sphincter is under somatic control. Pseudoachalasia is caused by extrinsic compression (most commonly by esophageal cancer). Gastric motility disorders include gastroparesis (delayed gastric emptying) and functional dyspepsia. Functional dyspepsia is divided into epigastric pain syndrome and postprandial distress syndrome. Treatment follows a stepwise approach: test for H. pylori and treat if positive; if negative, empiric PPI for 8 weeks; if no response, consider tricyclic antidepressants, prokinetics, or psychological interventions.

GI motor function disturbances encompass three main categories: esophageal motility disorders (including achalasia, diffuse esophageal spasm, and CREST syndrome), gastric motility disorders (delayed gastric emptying/gastroparesis, rapid gastric emptying/dumping syndrome, and functional dyspepsia), and intestinal motility disorders (including constipation, irritable bowel syndrome, and malabsorption syndromes). These conditions result from primary motility defects or secondary causes such as diabetes, scleroderma, hypothyroidism, infections, medications, and psychological factors. Diagnosis relies on clinical evaluation, imaging (barium studies), endoscopy, manometry, and specialized tests like the smart pill wireless motility capsule. Treatment approaches vary by condition but commonly include lifestyle modifications, dietary adjustments, pharmacotherapy, and in some cases, endoscopic or surgical interventions.